Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 4;24(1):19.
doi: 10.1208/s12248-021-00644-3.

Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review

Affiliations
Review

Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review

Sheela Kolluri et al. AAPS J. .

Abstract

Over the past decade, artificial intelligence (AI) and machine learning (ML) have become the breakthrough technology most anticipated to have a transformative effect on pharmaceutical research and development (R&D). This is partially driven by revolutionary advances in computational technology and the parallel dissipation of previous constraints to the collection/processing of large volumes of data. Meanwhile, the cost of bringing new drugs to market and to patients has become prohibitively expensive. Recognizing these headwinds, AI/ML techniques are appealing to the pharmaceutical industry due to their automated nature, predictive capabilities, and the consequent expected increase in efficiency. ML approaches have been used in drug discovery over the past 15-20 years with increasing sophistication. The most recent aspect of drug development where positive disruption from AI/ML is starting to occur, is in clinical trial design, conduct, and analysis. The COVID-19 pandemic may further accelerate utilization of AI/ML in clinical trials due to an increased reliance on digital technology in clinical trial conduct. As we move towards a world where there is a growing integration of AI/ML into R&D, it is critical to get past the related buzz-words and noise. It is equally important to recognize that the scientific method is not obsolete when making inferences about data. Doing so will help in separating hope from hype and lead to informed decision-making on the optimal use of AI/ML in drug development. This manuscript aims to demystify key concepts, present use-cases and finally offer insights and a balanced view on the optimal use of AI/ML methods in R&D.

Keywords: Artificial intelligence; Clinical trial design; Drug development; Machine learning; Precision medicine; Predictive modeling; Probability of success; Risk-based monitoring.

PubMed Disclaimer

Conflict of interest statement

Sheela K. was previously employed by Takeda Pharmaceuticals and is currently employed by Teva Pharmaceuticals (West Chester PA USA) during the development and revision of this manuscript. All other authors are employed by Takeda Pharmaceuticals during the development and revision of this manuscript.

Figures

Fig. 1
Fig. 1
Chronology of AI and ML
Fig. 2
Fig. 2
Brief overview of AI
Fig. 3
Fig. 3
Brief overview of supervised and unsupervised learning
Fig. 4
Fig. 4
Application of ML/AI based on the dimensionality of the data
Fig. 5
Fig. 5
Application of ML/AI based on various aspects of drug development

Similar articles

Cited by

References

    1. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33. doi: 10.1016/j.jhealeco.2016.01.012. - DOI - PubMed
    1. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–286. doi: 10.1093/biostatistics/kxx069. - DOI - PMC - PubMed
    1. Russell S, Norvig P. Artificial intelligence: a modern approach (4th edition), 2021; Pearson Series in Artificial Intelligence.
    1. Mitchell A, Sharma Y, Ramanathan S, Sethuraman V. Is data science the treatment for inefficiencies in clinical trial operations? White paper. https://www.zs.com/insights/is-data-science-the-treatment-for-inefficien....
    1. Dill KA and MacCallum JL. The protein-folding problem, 50 years on. Science. 2012;338(6110):1042–6. 10.1126/science.1219021. - PubMed